instruction
stringlengths 39
316
| response
stringlengths 121
336
| text
stringlengths 194
685
|
|---|---|---|
I’d like to know the median PFS of Melphalan, Autologous PBSCT, Placebo. | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: I’d like to know the median PFS of Melphalan, Autologous PBSCT, Placebo.
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
Do you have information on the median PFS of Melphalan, Autologous PBSCT, Placebo? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: Do you have information on the median PFS of Melphalan, Autologous PBSCT, Placebo?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
What is the median progression-free survival (PFS) for Melphalan, Autologous PBSCT, Placebo? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: What is the median progression-free survival (PFS) for Melphalan, Autologous PBSCT, Placebo?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
Can you inform me about the median PFS for Melphalan, Autologous PBSCT, Placebo? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: Can you inform me about the median PFS for Melphalan, Autologous PBSCT, Placebo?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
I’m interested in the median PFS of Melphalan, Autologous PBSCT, Placebo. | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: I’m interested in the median PFS of Melphalan, Autologous PBSCT, Placebo.
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
Could you tell me the median PFS for Melphalan, Autologous PBSCT, Placebo? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: Could you tell me the median PFS for Melphalan, Autologous PBSCT, Placebo?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
What is the median PFS rate for Melphalan, Autologous PBSCT, Placebo? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: What is the median PFS rate for Melphalan, Autologous PBSCT, Placebo?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Melphalan, Autologous PBSCT, Placebo regimen? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Melphalan, Autologous PBSCT, Placebo regimen?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
What is the median PFS rate in patients who have undergone Melphalan, Autologous PBSCT, Placebo regimen? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: What is the median PFS rate in patients who have undergone Melphalan, Autologous PBSCT, Placebo regimen?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Melphalan, Autologous PBSCT, Placebo regimen? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Melphalan, Autologous PBSCT, Placebo regimen?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
What’s the median PFS rate for patients receiving Melphalan, Autologous PBSCT, Placebo regimen? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: What’s the median PFS rate for patients receiving Melphalan, Autologous PBSCT, Placebo regimen?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
Could you provide the median Progression-Free Survival rate for patients treated with Melphalan, Autologous PBSCT, Placebo regimen? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Melphalan, Autologous PBSCT, Placebo regimen?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
What is the median rate of Progression-Free Survival in patients who have been treated with Melphalan, Autologous PBSCT, Placebo regimen? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Melphalan, Autologous PBSCT, Placebo regimen?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
Can you inform me about the median PFS rate in patients that were treated with Melphalan, Autologous PBSCT, Placebo regimen? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Melphalan, Autologous PBSCT, Placebo regimen?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
What is the median PFS rate for patients that have undergone Melphalan, Autologous PBSCT, Placebo regimen? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: What is the median PFS rate for patients that have undergone Melphalan, Autologous PBSCT, Placebo regimen?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
Could you tell me the median Progression-Free Survival rate for patients who received Melphalan, Autologous PBSCT, Placebo regimen? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Melphalan, Autologous PBSCT, Placebo regimen?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
What’s the median rate of PFS in patients treated with Melphalan, Autologous PBSCT, Placebo regimen? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: What’s the median rate of PFS in patients treated with Melphalan, Autologous PBSCT, Placebo regimen?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
Can you share the median Progression-Free Survival rate in patients who have received Melphalan, Autologous PBSCT, Placebo regimen? | Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Melphalan, Autologous PBSCT, Placebo regimen?
### Response: Patients treated with the Melphalan, Autologous PBSCT, Placebo have a median Progression-Free Survival (PFS) rate of 28.9 months, with a 95% CI of (22.0, 36.3). |
Can you tell me the median PFS for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: Can you tell me the median PFS for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
What’s the median PFS associated with Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: What’s the median PFS associated with Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
Could you provide the median PFS of Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: Could you provide the median PFS of Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
I’d like to know the median PFS of Bortezomib+Dexamethasone (Vd). | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: I’d like to know the median PFS of Bortezomib+Dexamethasone (Vd).
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
Do you have information on the median PFS of Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: Do you have information on the median PFS of Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
What is the median progression-free survival (PFS) for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: What is the median progression-free survival (PFS) for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
Can you inform me about the median PFS for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: Can you inform me about the median PFS for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
I’m interested in the median PFS of Bortezomib+Dexamethasone (Vd). | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: I’m interested in the median PFS of Bortezomib+Dexamethasone (Vd).
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
Could you tell me the median PFS for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: Could you tell me the median PFS for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
What is the median PFS rate for Bortezomib+Dexamethasone (Vd)? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: What is the median PFS rate for Bortezomib+Dexamethasone (Vd)?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
What is the median PFS rate in patients who have undergone Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: What is the median PFS rate in patients who have undergone Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
What’s the median PFS rate for patients receiving Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: What’s the median PFS rate for patients receiving Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
What is the median PFS rate for patients that have undergone Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: What is the median PFS rate for patients that have undergone Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
What’s the median rate of PFS in patients treated with Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: What’s the median rate of PFS in patients treated with Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Dexamethasone (Vd) regimen? | Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Bortezomib+Dexamethasone (Vd) regimen?
### Response: Patients treated with the Bortezomib+Dexamethasone (Vd) have a median Progression-Free Survival (PFS) rate of 7.1 months, with a 95% CI of (6.2, 7.9). |
Can you tell me the median PFS for Daratumumab? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: Can you tell me the median PFS for Daratumumab?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
What’s the median PFS associated with Daratumumab? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: What’s the median PFS associated with Daratumumab?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
Could you provide the median PFS of Daratumumab? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: Could you provide the median PFS of Daratumumab?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
I’d like to know the median PFS of Daratumumab. | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: I’d like to know the median PFS of Daratumumab.
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
Do you have information on the median PFS of Daratumumab? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: Do you have information on the median PFS of Daratumumab?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
What is the median progression-free survival (PFS) for Daratumumab? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: What is the median progression-free survival (PFS) for Daratumumab?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
Can you inform me about the median PFS for Daratumumab? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: Can you inform me about the median PFS for Daratumumab?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
I’m interested in the median PFS of Daratumumab. | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: I’m interested in the median PFS of Daratumumab.
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
Could you tell me the median PFS for Daratumumab? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: Could you tell me the median PFS for Daratumumab?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
What is the median PFS rate for Daratumumab? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: What is the median PFS rate for Daratumumab?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab regimen? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Daratumumab regimen?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
What is the median PFS rate in patients who have undergone Daratumumab regimen? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: What is the median PFS rate in patients who have undergone Daratumumab regimen?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab regimen? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Daratumumab regimen?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
What’s the median PFS rate for patients receiving Daratumumab regimen? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: What’s the median PFS rate for patients receiving Daratumumab regimen?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab regimen? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Daratumumab regimen?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab regimen? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Daratumumab regimen?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
Can you inform me about the median PFS rate in patients that were treated with Daratumumab regimen? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Daratumumab regimen?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
What is the median PFS rate for patients that have undergone Daratumumab regimen? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: What is the median PFS rate for patients that have undergone Daratumumab regimen?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab regimen? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Daratumumab regimen?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
What’s the median rate of PFS in patients treated with Daratumumab regimen? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: What’s the median rate of PFS in patients treated with Daratumumab regimen?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
Can you share the median Progression-Free Survival rate in patients who have received Daratumumab regimen? | Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Daratumumab regimen?
### Response: Patients treated with the Daratumumab have a median Progression-Free Survival (PFS) rate of Not Reached months, with a 95% CI of (NE, NE). |
Can you tell me the median PFS for Observation Only? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: Can you tell me the median PFS for Observation Only?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
What’s the median PFS associated with Observation Only? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: What’s the median PFS associated with Observation Only?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
Could you provide the median PFS of Observation Only? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: Could you provide the median PFS of Observation Only?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
I’d like to know the median PFS of Observation Only. | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: I’d like to know the median PFS of Observation Only.
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
Do you have information on the median PFS of Observation Only? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: Do you have information on the median PFS of Observation Only?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
What is the median progression-free survival (PFS) for Observation Only? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: What is the median progression-free survival (PFS) for Observation Only?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
Can you inform me about the median PFS for Observation Only? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: Can you inform me about the median PFS for Observation Only?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
I’m interested in the median PFS of Observation Only. | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: I’m interested in the median PFS of Observation Only.
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
Could you tell me the median PFS for Observation Only? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: Could you tell me the median PFS for Observation Only?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
What is the median PFS rate for Observation Only? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: What is the median PFS rate for Observation Only?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Observation Only regimen? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Observation Only regimen?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
What is the median PFS rate in patients who have undergone Observation Only regimen? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: What is the median PFS rate in patients who have undergone Observation Only regimen?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Observation Only regimen? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Observation Only regimen?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
What’s the median PFS rate for patients receiving Observation Only regimen? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: What’s the median PFS rate for patients receiving Observation Only regimen?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
Could you provide the median Progression-Free Survival rate for patients treated with Observation Only regimen? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Observation Only regimen?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
What is the median rate of Progression-Free Survival in patients who have been treated with Observation Only regimen? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Observation Only regimen?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
Can you inform me about the median PFS rate in patients that were treated with Observation Only regimen? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Observation Only regimen?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
What is the median PFS rate for patients that have undergone Observation Only regimen? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: What is the median PFS rate for patients that have undergone Observation Only regimen?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
Could you tell me the median Progression-Free Survival rate for patients who received Observation Only regimen? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Observation Only regimen?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
What’s the median rate of PFS in patients treated with Observation Only regimen? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: What’s the median rate of PFS in patients treated with Observation Only regimen?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
Can you share the median Progression-Free Survival rate in patients who have received Observation Only regimen? | Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). | ### Instruction: Can you share the median Progression-Free Survival rate in patients who have received Observation Only regimen?
### Response: Patients treated with the Observation Only have a median Progression-Free Survival (PFS) rate of 46.7 months, with a 95% CI of (40, NE). |
Can you tell me the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: Can you tell me the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
What’s the median PFS associated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: What’s the median PFS associated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
Could you provide the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: Could you provide the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
I’d like to know the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd). | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: I’d like to know the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
Do you have information on the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: Do you have information on the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
What is the median progression-free survival (PFS) for Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: What is the median progression-free survival (PFS) for Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
Can you inform me about the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: Can you inform me about the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
I’m interested in the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd). | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: I’m interested in the median PFS of Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd).
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
Could you tell me the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: Could you tell me the median PFS for Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
What is the median PFS rate for Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: What is the median PFS rate for Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd)?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: What is the median Progression-Free Survival (PFS) rate in patients treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
What is the median PFS rate in patients who have undergone Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: What is the median PFS rate in patients who have undergone Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: Can you tell me the median Progression-Free Survival rate in patients who were treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
What’s the median PFS rate for patients receiving Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: What’s the median PFS rate for patients receiving Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: Could you provide the median Progression-Free Survival rate for patients treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: What is the median rate of Progression-Free Survival in patients who have been treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: Can you inform me about the median PFS rate in patients that were treated with Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
What is the median PFS rate for patients that have undergone Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: What is the median PFS rate for patients that have undergone Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen? | Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). | ### Instruction: Could you tell me the median Progression-Free Survival rate for patients who received Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) regimen?
### Response: Patients treated with the Pomalidomide+Bortezomib+Dexamethasone (PVd) or
Daratumumab+Pomalidomide+Dexamethasone (DPd) have a median Progression-Free Survival (PFS) rate of 11.8 months, with a 95% CI of (0.18, 0.38). |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.